EUCTR2021-002325-18-IT进行中（未招募）1 期
Multicenter phase II study of preoperative chemoradiotherapy with CApecitabine plus Temozolomide in patients with MGMT silenced and microsatellite stable locally Advanced RecTal Cancer: the CATARTIC trial - CATARTIC Study
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 21
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Written informed consent to study procedures;
- •-Age = 18 years;
- •-ECOG PS 0-1;
- •-Life expectancy of at least 5 years (excluding diagnosis of cancer);
- •-Histologically confirmed diagnosis of rectal adenocarcinoma, with centrally confirmed mismatch repair proficiency by multiplex polymerase chain reaction (PCR), lack of MGMT expression by immunohistochemistry and MGMT promoter methylation by pyrosequencing;
- •-Locally advanced, resectable disease defined by the presence of at least one of the following features:
- •oDistal tumor margin at <15 cm from the anal verge;
- •ocT3N0 or cT1-3N1(with the definition of a clinically positive lymph node being any node = 1 cm);
- •oLess than four lymph nodes in the mesorectum showing morphological signs on MRI indicating metastatic disease;
- •oNo evidence of enlarged lateral pelvic clinically positive lymph node (> 1 cm);
- •oNo evidence of extramural vascular invasion (EMVI);
- •oNo evidence of metastatic disease by CT scan of the chest and abdomen and total body FDG PET/CT scan;
- •oNo clear indication of involvement of the pelvic side walls by imaging;
- •-Tumor must be amenable to curative resection (curative resection can include pelvic exenteration);
- •-Hematopoietic: absolute neutrophil count =1500/mm3; platelet count = 100,000/mm3; haemoglobin level = 10 g/dL;
- •-Hepatic total bilirubin =1.5 time upper limit of normal (ULN); alkaline phosphatase = 2 times ULN; AST and ALT = 2.5 times ULN Serum creatinine = 1.5 × ULN or renal creatinine clearance = 50 mL/min according to the Cockcroft-Gault formula (or local institutional standard methods).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 21
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •-Dihydropyrimidine dehydrogenase (DPD) deficiency;
- •-Previous pelvic RT;
- •-Any of the following in the 6 months prior to treatment start: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure (= New York Heart Association Classification Class II), cerebrovascular accident/stroke, transient ischemic attack, serious cardiac arrhythmia requiring medication or symptomatic pulmonary embolism;
- •-Uncontrolled coagulopathy;
- •-Active infection requiring systemic therapy;
- •-Infection with human immunodeficiency virus (HIV) plus CD4 cells <200/mm3 or AIDS-defining conditions despite HAART;
- •-Lack of upper gastrointestinal tract integrity or malabsorption syndrome; immune colitis; active inflammatory bowel disease (i.e., patients requiring current medical interventions or who are symptomatic);
- •-Patients with prior malignancies (with the exception of rectal cancer), including invasive colon cancer, are eligible provided they have been disease-free for = 3 years and are deemed by their physician to be at low risk for recurrence (patients with effectively treated squamous cell or basal cell skin cancer, melanoma in situ, carcinoma in situ of the cervix, or carcinoma in situ of the colon or rectum are eligible even if diagnosed less than 3 years before study enrollment);
- •-Other severe acute or chronic medical conditions including immune pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study;
- •-Any concomitant drugs contraindicated for use with the trial drugs according to the product information of the pharmaceutical companies;
- •-Pregnant or lactating women.
研究者
相似试验
进行中（未招募）
1 期
Multicenter phase II study of preoperative chemoradiotherapy with CApecitabine plus Temozolomide in patients with MGMT silenced and microsatellite stable locally Advanced RecTal Cancer: the CATARTIC triallocally advanced rectal cancer (LARC)MedDRA version: 20.0Level: HLTClassification code: 10010023Term: Colorectal neoplasms malignant Class: 10029104CTIS2024-513931-26-00Fondazione IRCCS Istituto Nazionale Dei Tumori21
已完成
2 期
A phase II study of preoperative concurrent chemoradiotherapy with TS-1/ Oxaliplatin in patients with locally advanced rectal cancer(PerSeUS-RC01)locally advanced rectal cancerJPRN-UMIN000011861PerSeUS:Perpetual Study estimated-by United Sections in Gifu40
招募中
2 期
A phase II study of preoperative concurrent chemoradiation therapy for patients with locally advanced rectal cancerectal cancerJPRN-UMIN000004104Hamamatsu University School of Medicine, Second department of Surgery30
招募中
2 期
A Phase II study of preoperative concurrent chemoradiotherapy with TS-1 in patients with locally advanced lower rectal cancer.ocally-advanced lower rectal cancerJPRN-UMIN000006242ara Hospital Kinki University Faculty of Medicine20
招募中
不适用
A phase 2 clinical trial of preoperative chemoradiation therapy for locally advanced low rectal cancer with limited radiation field to the lesser pelvisocally advanced low rectal cancerJPRN-UMIN000013383Gunma University Graduate School of Medicine52